Millennium Pharmaceuticals Limited

Harvard College

University of Toronto

Takeda Gmbh

Takeda Pharmaceutical Company Limited

Kumacheva, Eugenia

Willow Ruth Diluzio

Nobel T Truong

George M Whitesides

Darren Roy Link

David A Weitz

Jason W Brown

Howard A Stone

Eugenia Kumacheva

Irina Gitlin

Vaithianathan Palaniappan

Csanad M Varga

Shelley L Anna

Donald Rogers, Jr

Sarah Royalty Tredo

Piotr Garstecki

Nathalie Bontoux

Phoung M Nguyen

Phuong Nguyen

Catherine Rose Scholz

Irving H Fox

Catherine Scholz

Maria Rosario

Shelly L Anna

Phuong M Nguyen

Autoinjector

Antibody formulations are described comprising a mixture of an anti-&#x3b1;4&#x3b2;7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-&#x3b1;4&#x3b2;7 antibody in vivo.

Formulation for anti-&#x3b1;4&#x3b2;7 antibody

The present invention relates to aqueous formulations comprising a compound neutralizing GM-CSF in concentrations of at least 20 mg/ml, a tonicity modifier, a buffer and one or more of surfactants, amino acids, antioxidants and/or chelators, wherein the composition is stable. The ingredients of the formulation preferably provide stability to the compound neutralizing GM-CSF in view of long-term storage. In a preferred aspect, the formulation is for use in therapy, preferably for use in the treatment of inflammatory and autoimmune disorders, preferably including allergic and psoriatic disorders, as well as arthritic and asthmatic disorders.

Liquid formulation comprising GM-CSF neutralizing compound

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-&#x3b1;4&#x3b2;7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-&#x3b1;4&#x3b2;7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-&#x3b1;4&#x3b2;7 antibody in vivo.

A microfluidic method and device for focusing and/or forming discontinuous sections of similar or dissimilar size in a fluid is provided. The device can be fabricated simply from readily-available, inexpensive material using simple techniques.

Method and apparatus for fluid dispersion

Growing community of inventors

Gloucester, MA, United States of America

Willow Ruth Diluzio